Form 4: NewAmsterdam Pharma Co N.V. Executive Louise Kooij Reports Transaction in Ordinary Shares

Sentiment:

SEC Form 4 Filing


Louise Kooij, Chief Accounting Officer of NewAmsterdam Pharma Co N.V., reports the acquisition and disposition of ordinary shares and derivative securities.

Summary

  • On March 4, 2025, Louise Kooij, the Chief Accounting Officer of NewAmsterdam Pharma Co N.V., reported transactions involving the company's ordinary shares.
  • Kooij acquired 150,000 ordinary shares through the exercise of an option.
  • Simultaneously, Kooij disposed of 150,000 ordinary shares at a price of $20.37 per share.
  • Following these transactions, Kooij directly owns 15,000 ordinary shares.
  • Kooij also reported holding 18,073 derivative securities (options) exercisable for ordinary shares.
  • The option was granted on November 22, 2022, replacing a previous option from July 6, 2021, with an exercise price of EUR 1.16392.
  • 60,879 of the shares underlying the option immediately vested on the grant date, with the remaining shares vesting over three years.

Sentiment

Score: 5

Explanation: This is a neutral report of transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure related to insider trading activity, which is common for publicly traded companies. It provides transparency into the transactions of company executives.

Stakeholder Impact

  • The transaction provides transparency to shareholders regarding executive stock ownership.
  • The sale of shares may have a minor impact on the stock price.

Key Dates

DateDescription
2021-07-06Original option grant date (later cancelled).
2022-11-22Option granted to replace the original option.
2025-03-04Date of transaction (acquisition and disposition of shares).
2025-03-05Date of signature on the Form 4.
2031-07-06Expiration date of the option.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.